UBS lowered the firm’s price target on Treace Medical (TMCI) to $2.25 from $2.50 and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical price target lowered to $7 from $7.50 at Lake Street
- Treace Medical reports Q4 EPS (15c), consensus (15c)
- Treace Medical sees FY26 revenue $200M-$212M, consensus $210.31M
- Treace Medical to highlight new product innovations, present data at ACFAS
- Treace Medical Issues Preliminary Q4 Results, Highlights Growth